Alternative therapies for chronic bronchitis

American Journal of the Medical Sciences

Volumn 318, Issue 2, 1999, Pages 96-98

  Jones, Kimberly L ^a   Robbins, Richard A ^b  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b OVERTON BROOKS VA MEDICAL CENTER   (United States)

Author keywords

Anti proteases; Antioxidants; Expectorants; Immunostimulants; Mucolytics

Indexed keywords

ANTIOXIDANT; EXPECTORANT AGENT; IMMUNOSTIMULATING AGENT; MUCOLYTIC AGENT; PROTEINASE INHIBITOR;

CHRONIC BRONCHITIS; CONFERENCE PAPER; DRUG ACTIVITY; DRUG INDICATION; DRUG USE; HUMAN;

EID: 0033499342     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40589-0     Document Type: Conference Paper

References (29)

1. Stoller JK, Aboussouan LS. Chronic obstructive lung diseases: emphysema, chronic bronshitis, bronchiectasis, and cystic fibrosis. In: George R, Light R, Matthay RA, Matthay MA, editors. Chest medicine: essentials of pulmonary and critical care medicine. 3rd ed. Baltimore: Williams and Wilkins; 1995. p. 201-46.
2. Adam PF, Benson V. Current estimates from the National Health Interview Survey, 1991. Vital Health Stat 10 1992; (184):1-232.
3. Murray JF, Nadel JA. Textbook of respiratory medicine. Philadelphia. W.B. Saunders; 1994. p. 1331-97.
4. Task Group on Mucoactive Drugs. Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Chest 1994;106:1532-7.
5. Ziment, I. Pharmacologic therapy of obstructive airway disease. Clin Chest Med 1990;11:461-86.
6. Rubin BK, Van Der Schans CP, Kifhioka C, et al. Mucus, and mucoactive therapy in chronic bronchitis. Clin Pul Med 1998;5:1-14.
7. Petty TL. National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;97:75-83.
8. Repsher LH. treatment of stable chronic bronchitis with iodinated glycerol: a double-blind, placebo-controlled trial. J Clin Pharmacol 1993;33:856-60.
9. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable bronchitis. Chest 1996;109: 348-52.
10. Becker CB, Gordon JM. Iodinated glycerol and thyroid dysfunction. Chest 1993;103:188-92.
11. Bowman G, Backer U, Larsson S, et al. Oral acetylcysteine reduces exacerbation rates in chronic bronchitis: report of the trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983;64:405-15.
12. Hansen NCG, Skriver A, Brorsen-Riis L. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994;88:531-5.
13. Dueholm M, Nielson C, Thorshauge H. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med 1992;86:89-92.
14. Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 1990;87:9188-92.
15. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993;148:145-51.
16. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effects of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
17. Bone RC, Fuchs H, Fox NL, et al. The chronic obstructive pulmonary disease mortality end point trial [abstract]. Chest 1995;108 (3 suppl):R.
18. Wills PJ, Wadehouse T, Corkery K, et al. Short term recombinant human DNase in bronchiectasis. Am J Respir Crit Care Med 1996;154:413-7.
19. Higenbottam T. Pulmonary surfactant and chronic lung disease. Eur J Respir Dis 1987;71:222-8.
20. Anzueto A, Jubran A, Ohar JA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997;278:1426-31.
21. Janoff A. Elastases and emphysema: current assessment of the protease antiprotease hypothesis. Am Rev Respir Dis 1985;132:417-33.
22. Travis J, Owen M. Isolation and properties of recombinant DNA produced variants of human αl-proteinase inhibitor. J Biol Chem 1985;260:4384-9.
23. Crystal RG. Gene therapy strategies for pulmonary disease. Am J Med 1992;92:448-528.
24. Eriksson S. The potential role of elastase inhibitors in emphysema treatment. Eur Respir J 1991;4:1041-3.
25. Repine JE, Bast A, Lankhorst I, et al. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:341-57.
26. Lundbäck BM, Linström M, Andersson S, et al. Possible effect of acetylcysteine on lung function. Eur Respir J 1995; 5:895.
27. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987;136:225-44.
28. Fietta A, Bersani C, DeRose V, et al. Double-blind trial of RU 41740 vs. placebo: immunologic and clinical effects in a group of patients with chronic bronchitis. Respiration 1988; 56:145-52.
29. Orcel B, Delclaux B, Baud M, et al. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 1994;7:446-52.